References
- National Heart, Lung, and Blood Institute. What is sickle cell disease? Bethesda (MD); 2022 Mar 24 [accessed 2022 Jan 17]. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease.
- Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–31. doi:10.1016/S0140-6736(10)61029-X.
- Centers for Disease Control and Prevention. What is sickle cell disease?. Washington (DC); 2022 Jun 7 [accessed 2022 Jun 10]. https://www.cdc.gov/ncbddd/sicklecell/facts.html.
- Borhade MB, Kondamudi NP. StatPearls Publishing. Sickle cell crisis. Treasure Island (FL); 2021 Jul 1 [accessed 2022 Jan 17]. https://www.ncbi.nlm.nih.gov/books/NBK526064/.
- Shah SP, Twilla JD, Kemp L, Phelps GL, Reaves A. Comparison of parenteral opioid dosing in adult sickle cell disease patients with vaso-occlusive crisis. J Pain Palliat Care Pharmacother. 2018;32(4):201–7. doi:10.1080/15360288.2019.1577938.
- Tanabe P, Spratling R, Smith D, Grissom P, Hulihan M. CE: understanding the complications of sickle cell disease. Am J Nurs. 2019;119(6):26–35. doi:10.1097/01.NAJ.0000559779.40570.2c.
- Brandow AM, Carroll CP, Creary S, Edwards-Elliott R, Glassberg J, Hurley RW, Kutlar A, Seisa M, Stinson J, Strouse JJ, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656–701. doi:10.1182/bloodadvances.2020001851.
- Centers for Disease Control and Prevention. Healthcare Utilization for Vaso-occlusive Episodes. Washington (DC); 2020 May 7 [accessed 2022 Mar 9]. https://www.cdc.gov/ncbddd/hemoglobinopathies/scdc-voe-data-brief.html.
- Averbukh Y, Porrovecchio A, Southern WN. Patient-controlled analgesia for vaso-occlusive crisis: a cohort study. Clin J Pain. 2019;35(8):686–90. doi:10.1097/AJP.0000000000000726.
- Cheng E, Floroff C, Ingemi AI, Vasist N, Ko A, Goodman BM. A comparison of two regimens for managing sickle cell pain and reducing readmissions. J Pain Palliat Care Pharmacother. 2021;35(3):143–9. doi:10.1080/15360288.2021.1925385.